Cargando…

PB1780: DIFFERENCES IN SECRETOME OF BONE MARROW MULTIPOTENT MESENCHYMAL STROMAL CELLS IN PATIENTS AT THE ONSET OF ACUTE MYELOID LEUKEMIA AND AFTER ACHIEVING REMISSION.

Detalles Bibliográficos
Autores principales:	Sadovskaya, Aleksandra, Petinati, Nataliya, Drize, Nina, Smirnov, Igor, Pobeguts, Olga, Arapidi, Georgiy, Lagarkova, Maria, Vasilieva, Anastsia, Gavrilina, Olga, Parovichnikova, Elena
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430321/ http://dx.doi.org/10.1097/01.HS9.0000973976.04333.84

Ejemplares similares

Acute Myeloid Leukemia Causes Serious and Partially Irreversible Changes in Secretomes of Bone Marrow Multipotent Mesenchymal Stromal Cells
por: Sadovskaya, Aleksandra, et al.
Publicado: (2023)

Multipotent Mesenchymal Stromal Cells from Porcine Bone Marrow, Implanted under the Kidney Capsule, form an Ectopic Focus Containing Bone, Hematopoietic Stromal Microenvironment, and Muscles
por: Petinati, Nataliya, et al.
Publicado: (2023)

Immunophenotypic characteristics of multipotent mesenchymal stromal cells that affect the efficacy of their use in the prevention of acute graft vs host disease
por: Petinati, Nataliya, et al.
Publicado: (2020)

PB2705: PROFESSIONAL BURNOUT AMONG HEMATOLOGISTS AFTER THE OUTBREAK OF THE COVID-19 PANDEMIC AND ASSOCIATED FACTORS
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

What do we know about the participation of hematopoietic stem cells in hematopoiesis?
por: Drize, Nina, et al.
Publicado: (2015)

PB2030: HYPERCHROMIC ANEMIA AS THE FIRST MANIFESTATION OF MYELOPROLIFERATIVE DISEASE
por: Lepkov, Sergey, et al.
Publicado: (2023)

PB1780: AN INNOVATIVE INTERACTIVE CASE-BASED ONLINE EDUCATION TOOL SUBSTANTIALLY INCREASES KNOWLEDGE AND COMPETENCE OF CLINICIANS MANAGING HIGH-RISK AML
por: Harvey-Jones, V., et al.
Publicado: (2022)

Hematopoiesis during Ontogenesis, Adult Life, and Aging
por: Belyavsky, Alexander, et al.
Publicado: (2021)

PB2257: SARS-COV-2 VARIANTS DETECTED IN EMPLOYEES OF ONE MEDICAL CENTER
por: Biderman, B., et al.
Publicado: (2022)

Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease—A Phase II Study
por: Kuzmina, Larisa A., et al.
Publicado: (2012)

PB1916: SOMATIC MUTATIONS ASSOCIATED WITH MYELODYSPLASTIC SYNDROME IN RUSSIAN PATIENTS
por: Kohno, A., et al.
Publicado: (2022)

PB2174: ON THE ROBUSTNESS OF THE BUCCAL EPITHELIUM FOR ASSESSING RECIPIENT DNA PROFILE IN PATIENTS AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION
por: Risinskaya, N., et al.
Publicado: (2022)

PB1844: THROMBOTIC EVENTS DURING REMISSION INDUCTION OF ACUTE MYELOID LEUKEMIA – FREQUENCY AND RELATED FACTORS
por: Silva, W., et al.
Publicado: (2022)

PB2564: COVID-19 AND FERRITIN
por: Kuiavovych, Bohdana, et al.
Publicado: (2023)

PB2653: SYNTHESIS OF MAGNETIC NANOPARTICLES SUITABLE FOR PURIFICATION FACTOR VIII
por: Shurko, Nataliya, et al.
Publicado: (2023)

PB1824: IMPACT OF DAY 15 BONE MARROW ASPIRATION ON PREDICTION OF COMPLETE REMISSION AND RELAPSE IN ACUTE MYELOID LEUKEMIA
por: Kharrat, R., et al.
Publicado: (2022)

PB2491: LANGERHANS CELL HISTIOCYTOSIS (LCH) IN THE MAXILLOFACIAL AREA IN ADULT. COMPLETE REMISSION WITH CLADRIBINE. CASE REPORT AND REVIEW.
por: De Miguel Llorente, Dunia, et al.
Publicado: (2023)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB1964: RELATIONSHIP BETWEEN SIRT1-7 AND SELECTED MIRNAS EXPRESSIONS IN MYELOMA/LYMPHOMA PATIENTS IN DIFFERENT REMISSION STATUS.
por: Nowicki, M., et al.
Publicado: (2022)

PB2291: EFFICACY OF SPLENECTOMY IN SPLENIC MARGINAL ZONE LYMPHOMA
por: Yevstakhevych, Yuriy, et al.
Publicado: (2023)

Recovery of Donor Hematopoiesis after Graft Failure and Second Hematopoietic Stem Cell Transplantation with Intraosseous Administration of Mesenchymal Stromal Cells
por: Petinati, Nataliya, et al.
Publicado: (2018)

PB1730: PROGNOSTIC VALUE OF EARLY T-ALL IMMUNOPHENOTYPES IN ADULTS ON THE RALL-2016 PROTOCOL
por: Vasileva, Anastasia, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB1970: LONG-TERM RESULTS OF THERAPY FOR CHRONIC MYELOID LEUKEMIA: A 20-YEAR ANALYSIS OF THE GIPAP PROGRAM IN RUSSIA
por: Shukhov, Oleg, et al.
Publicado: (2023)

PB2179: ALGORITM OF MOLECULAR GENETIC EXAMINATION OF PATIENTS WITH PH-NEGATIVE CRONIC MYELOPROLIFERATIVE NEOPLASM
por: Voroniak, Myroslav, et al.
Publicado: (2023)

Methylation profile of induced pluripotent stem cells generated by integration and integration-free approaches
por: Sultanov, Rinat, et al.
Publicado: (2018)

PB1906: HYPOMETHYLATING AGENT PLUS LOW DOSE VENETOCLAX – A CHEMOTHERAPY-FREE INDUCTION OF ACUTE MYELOID LEUKEMIA TO ACHIEVE COMPLETE REMISSION IN PATIENTS UNFIT FOR CHEMOTHERAPY
por: Kumar, Karthik, et al.
Publicado: (2023)

PB1740: THE COMBINATION OF PONATINIB PLUS CHEMOTHERAPY UPFRONT ACHIEVES DURABLE COMPLETE MOLECULAR REMISSIONS IN ADULTS PATIENTS WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA.
por: Sotirios, Papageorgiou, et al.
Publicado: (2023)

PB2023: THE LEVEL OF VASCULAR ENDOTHELIAL FACTOR (VEGF) IN THE BLOOD SERUM OF PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS RAEB I).
por: Стародуб, Галина, et al.
Publicado: (2023)

PB1837: ADDITION OF A THIRD, NON-TARGETED, AGENT TO CYTARABINE- AND ANTHRACYCLINE-BASED INDUCTION CHEMOTHERAPY FOR ACUTE MYELOBLASTIC LEUKEMIA INCREASES COMPLETE REMISSIONS AND TREATMENT-RELATED MORTALITY
por: Pereira, M., et al.
Publicado: (2022)

PB1899: OUTCOMES OF PATIENTS UNDERGOING TREATMENT FOR ACUTE MYELOID LEUKAEMIA SHOWING HIGH DEGREE OF PREDICTIVE ACCURACY ON THE EUROPEAN LEUKAEMIA NET (ELN) POST-REMISSION TREATMENT SCORE
por: Richardson, Michelle, et al.
Publicado: (2023)

PB1770: CHARACTERIZATION OF THE MUTATIONAL PROFILE OF PATIENTS WITH CBF-AML - HETEROGENEITY AND IMPACT ON THE PROGNOSIS
por: Motyko, Ekaterina, et al.
Publicado: (2023)

PB1883: TIME-LIMITED TREATMENT WITH ACALABRUTINIB PLUS OBINOTUZUMAB IN TREATMENT-NAÏVE CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS INDUCES DEEP REMISSIONS: EARLY RESULTS OF AN ONGOING PHASE 2 TRIAL.
por: Burger, J., et al.
Publicado: (2022)

PB1805: INSIGHTS FROM ORAL AZACITIDINE EARLY ACCESS PROGRAM IN FRANCE: PATIENT POPULATION WITH ACUTE MYELOID LEUKEMIA RECEIVING ORAL-AZA FOR MAINTENANCE OF COMPLETE REMISSION AFTER INDUCTION CHEMOTHERAPY
por: Raffoux, E., et al.
Publicado: (2022)

PB1962: INFLUENCE OF TRANSCRIPT TYPES IN SUSTAINED DEEP MOLECULAR RESPONSE (SDMR) AND TREATMENT-FREE REMISSION (TFR) IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS TREATED WITH TKI
por: Torra, Silvia Marce, et al.
Publicado: (2023)

PB1911: CYTOGENOMIC INTEGRATIVE ANALYSIS OF CLL/SLL PATIENTS AT DISEASE PROGRESSION.
por: García-Serra, Rocío, et al.
Publicado: (2023)

Culture and society, 1780-1950
por: Williams, Raymond
Publicado: (1979)

Culture and society, 1780-1950
por: Williams, Raymond
Publicado: (1979)

Proteomic Profiling of the Human Fetal Multipotent Mesenchymal Stromal Cells Secretome
por: Lobov, Arseniy A., et al.
Publicado: (2020)

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_8p2ia3jc4f41p8aug4rdas1jg8